RxDoctor Payments DataLook up a doctor →

Jeffrey Wolf, MD

Pulmonary Disease · Great Neck, NYNPI 1164460952

Payments from drug & device makers

$891,612in general payments, 2019–2025

Across 2,161 payments — averaging $412.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$173K
  • AstraZeneca$151K
  • GSK$140K
  • Regeneron Healthcare Solutions, Inc.$121K
  • Boehringer Ingelheim$87K
  • Mylan Specialty L.p.$76K
  • plus $142K from 50 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi207$173,391
AstraZeneca(2 entities)367$150,971
GSK309$140,059
Regeneron Healthcare Solutions, Inc.165$121,276
Boehringer Ingelheim220$87,490
Mylan Specialty L.p.157$76,467
Genentech USA, Inc.119$62,210
Viatris Specialty LLC44$34,607
Insmed, Inc.51$20,998
Advanced Respiratory, Inc31$8,029
Johnson & Johnson(2 entities)51$3,432
Philips North America LLC96$2,173
Sunovion Pharmaceuticals Inc.10$1,949
Grifols USA, LLC55$1,307
Novartis44$947
Mallinckrodt Hospital Products Inc.23$759
Actelion Pharmaceuticals US, Inc.21$689
Electromed, Inc.46$636
Baxter Healthcare21$582
Verona Pharma, Inc.13$404
Pulmonx Corporation2$293
Amgen14$263
Inspire Medical Systems, Inc.4$204
Mallinckrodt Enterprises LLC7$201
Noah Medical Corporation2$192
Inogen, Inc.8$171
Vifor Pharma, Inc.6$166
Pfizer9$154
Covidien LP1$154
Takeda Pharmaceuticals U.S.A., Inc.7$145
Medical Device Business Services, Inc.1$127
Medtronic1$127
Teva Pharmaceuticals USA, Inc.7$121
Harmony Biosciences LLC4$103
United Therapeutics Corporation5$96
Sanofi-aventis U.S. LLC5$87
Intuitive Surgical1$66
Regeneron1$53
Jazz Pharmaceuticals Inc.2$44
Boston Scientific2$42
Shire North American Group Inc2$40
Genentech, Inc.1$40
Circassia Inc.2$38
Gilead2$34
Paratek Pharmaceuticals, Inc.2$34
Chiesi USA, Inc.2$33
Cumberland Pharmaceuticals, Inc.2$32
Galvanize Therapeutics, Inc1$29
Optinose US, Inc.1$23
Merck1$21
Resmed Corp1$21
Phadia US Inc.1$20
ANI Pharmaceuticals, Inc.1$20
Shionogi Inc1$18
Veran Medical Technologies, Inc.1$15
3b Medical, Inc.1$9

How this compares

$891,612 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York →

Medicare billing

Part B allowed, 2024
$367,795
Medicare patients
860
Services billed
3,093

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Great Neck

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →